Filing Flows › Comparisons › BIAF vs ABSI
bioAffinity Technologies vs Absci: BIAF and ABSI compared
bioAffinity Technologies is the larger company: $1.1M of revenue in its latest quarter (Q3 2026) against $318K for Absci (Q2 2026). bioAffinity Technologies is growing faster (-26% against -46% a year earlier).
Where the money goes: BIAF and ABSI
bioAffinity Technologies (BIAF) · Q3 2026
bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%, net loss $5.3M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Absci (ABSI) · Q2 2026
Absci, Q2 2026: revenue $318K (-46% year over year), net loss $33.2M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
| bioAffinity Technologies (BIAF) | Absci (ABSI) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $1.1M | $318K |
| Revenue growth, Y/Y | -26% | -46% |
| Operating margin | -328.0% | n/m |
| Net earnings | −$5.3M | −$33.2M |
| Net margin | -493.1% | — |
| Operating cash flow | −$3.9M | −$27.6M |
Where the revenue comes from
bioAffinity Technologies
- Health Care, Patient Service: $863K (81%)
- Histology Service Fees: $190K (18%)
- Medical Director Fees: $17K (2%)
Questions
Which is bigger, bioAffinity Technologies or Absci?
bioAffinity Technologies is the larger company: $1.1M of revenue in its latest quarter (Q3 2026) against $318K for Absci (Q2 2026).
Is bioAffinity Technologies or Absci growing faster?
bioAffinity Technologies is growing faster (-26% against -46% a year earlier).
More: bioAffinity Technologies earnings · how bioAffinity Technologies makes money · Absci earnings · how Absci makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.